I think the approach needed is Proof of Concept for FTO for a small number of cancers. Say a patient population of 30 for each cancer. Randomised between low dose Bisantrene and SOC.
Bisantrene is known to be safe at high dose and there are early dose escalation studies.
Do enough to attract a partner for a larger trial.
Preclinical study geared specifically to cancer targets could also be enough to attract a partner.
Ann: Race appoints clinical & FDA regulatory strategy advisor, page-53
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |